Fig. 7
Therapeutically knocking-down GAS6-AS1 inhibits AML propagation and disease progression. A Representative PET images of tumor 18F-FDG uptake in leukemia-implanted mice after intra-tumoral injection of lentiviral vectors (n = 5 per group). B, C The weight and Ki-67 proliferation index in subcutaneous xenograft mice after lentiviral injection (red arrow: LeV-sh-Scb group; blue arrow: LeV-sh-GAS6-AS1 group). Data were depicted as mean ± s.e.m., *P < 0.05. D GAS6-AS1 knockdown impairs the tumorigenesis and infiltration of AML in vivo. H&E staining of bone morrow and spleen samples from mice xenotransplanted with U937 cells transfected with sh-Scb or sh-GAS6-AS1. E Flow cytometry showing declined levels of blasts in bone marrow from mice engrafted with GAS6-AS1-knockdown U937 cells compared with those in control group. CD11b marker expression was increased in sh-GAS6-AS1–treated group. F Scatter plots revealing the statistical values for panel E. G Kaplan-Meier survival curves for mice xenotransplanted with sh-Scb or sh-GAS6-AS1 U937 cells (n = 5 per group). P values were calculated using a log-rank (Mantel-Cox) test. H Schematic illustration of the mechanisms underlying GAS6-AS1 related oncogenic axis and therapeutic strategy